01—Abstract
Summary
Summary of the 10-Q filed October 31, 2024. Cited figures are marked; the original filing is the authoritative source.
Regeneron Pharmaceuticals, Inc. reported solid financial results for the nine months ended September 30, 2024, with total revenues reaching $10.41 billiona, an increase of 7.5% compared to the same period in the prior year.
Net income also saw a significant rise, up 25% to $3.49 billionb. This growth was driven by strong performance across key products, notably Dupixent and EYLEA HD, which showed substantial revenue increases of 25% and approximately 4% respectively in their respective segments. The company also saw positive growth in Libtayo and Praluent.
Research and development expenses increased by approximately 14% year-over-year, reflecting continued investment in the company's pipeline. The company ended the period with a strong liquidity position, with $2.01 billionc in cash and cash equivalents and $16.28 billion in marketable securities, while also actively repurchasing shares under its authorized program.
02—Key points
Key Highlights
- Total revenues for the nine months ended September 30, 2024, increased by 7.5% to $10.41 billion, driven by strong product sales and collaboration revenues.
- Net income for the nine months ended September 30, 2024, rose by 25% to $3.49 billion, resulting in diluted earnings per share of $30.23.
- Dupixent and Kevzara collaboration revenue experienced a significant increase of 23%, reflecting strong global sales performance.
- EYLEA HD and EYLEA U.S. net product sales increased by 3.1% to $4.47 billion for the nine months ended September 30, 2024, driven by the launch of EYLEA HD.
- Research and development expenses increased by 14% to $3.72 billion for the nine months ended September 30, 2024, indicating continued investment in pipeline development.
- The company repurchased $1.64 billion of its common stock during the nine months ended September 30, 2024, under its share repurchase program.
- Regeneron maintained a strong liquidity position with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities as of September 30, 2024.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-QQ3 FY2024filed October 31, 2024Financial Statements
Q3 FY2024 against Q3 FY2023
| Line item | Q3 FY2024Q3 FY2023 | Change |
|---|---|---|
| Revenue | $3.72B$3.36B | +10.6% |
| R&D Expenses | $1.27B$1.08B | +18.2% |
| SG&A Expenses | $714.40M$640.50M | +11.5% |
| Operating Expenses | $2.54B$2.25B | +12.9% |
| Operating Income | $1.18B$1.11B | +6.2% |
| Net Income | $1.34B$1.01B | +33.0% |
| EPS (Basic) | $12.40$9.48 | +30.8% |
| EPS (Diluted) | $11.54$8.89 | +29.8% |
| Shares Outstanding (Basic) | 108.10M106.30M | +1.7% |
| Shares Outstanding (Diluted) | 116.20M113.40M | +2.5% |
05—Questions
Frequently Asked Questions
What were the main drivers of Regeneron's revenue growth in the first nine months of 2024?
Regeneron's revenue growth was primarily driven by strong performance in collaboration revenues, particularly from Dupixent and Kevzara, which saw a 23% increase. Additionally, net product sales for EYLEA HD and EYLEA in the U.S. increased by 3.1%, and Libtayo and Praluent also showed positive sales growth.
How has the company's investment in research and development changed?
Research and development expenses increased by approximately 14% for the nine months ended September 30, 2024, compared to the same period in 2023, totaling $3.72 billion. This indicates a continued commitment to advancing its product pipeline.
What is the company's financial position and liquidity as of September 30, 2024?
As of September 30, 2024, Regeneron maintained a strong financial position with $2.01 billion in cash and cash equivalents and $16.28 billion in marketable securities. The company also had $1.98 billion in long-term debt.
Has Regeneron been actively returning capital to shareholders?
Yes, Regeneron repurchased $1.64 billion of its common stock during the nine months ended September 30, 2024, under its authorized share repurchase program. As of that date, $2.89 billion remained available under a recently authorized repurchase program.
06—Continue